<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TOBRAMYCIN - tobramycin sulfate injection, solution </strong><br>Fresenius Kabi USA, LLC<br></p></div>
<h1>Tobramycin Injection USP</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="b1e05895-f6b8-435b-bae2-014abe7ae553"></a><a name="section-1"></a><p></p>
<p class="First">Rx only </p>
<table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless"><tr class="First Last"><td class="Lrule Rrule" valign="top">
<span class="Bold">PHARMACY BULK PACKAGE —</span><span class="Bold">NOT FOR DIRECT INFUSION</span><br>             </td></tr></tbody></table>
<p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tobramycin Injection, USP and other antibacterial drugs, Tobramycin Injection, USP should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.</p>
<p><span class="Bold">This vial is intended for use by the hospital pharmacist in the extemporaneous preparation of IV solutions.</span></p>
</div>
<div class="Warning">
<a name="e39027dd-5649-49e2-8148-f657881ea076"></a><a name="section-2"></a><p></p>
<h1>BOXED WARNING</h1>
<p class="First">Patients treated with tobramycin and other aminoglycosides should be under close clinical observation, because these drugs have an inherent potential for causing <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">ototoxicity</span> and <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">Neurotoxicity</span>, manifested as both auditory and vestibular <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">ototoxicity</span>, can occur.  The auditory changes are irreversible, are usually bilateral, and may be partial or total.  Eighth-nerve impairment and <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> may develop, primarily in patients having pre-existing renal damage and in those with normal renal function to whom aminoglycosides are administered for longer periods or in higher doses than those recommended.  Other manifestations of <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span> may include <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, skin <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">muscle twitching</span>, and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>.  The risk of aminoglycoside-induced <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span> increases with the degree of exposure to either high peak or high trough serum concentrations.  Patients who develop cochlear damage may not have symptoms during therapy to warn them of eighth-nerve toxicity, and partial or total irreversible bilateral <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">deafness</span> may continue to develop after the drug has been discontinued.</p>
<p>Rarely, <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> may not become apparent until the first few days after cessation of therapy.  Aminoglycoside-induced <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> usually is reversible.</p>
<p>Renal and eighth-nerve function should be closely monitored in patients with known or suspected <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and also in those whose renal function is initially normal but who develop signs of renal dysfunction during therapy.  Peak and trough serum concentrations of aminoglycosides should be monitored periodically during therapy to assure adequate levels and to avoid potentially toxic levels.  Prolonged serum concentrations above 12 mcg/mL should be avoided.  Rising trough levels (above 2 mcg/mL) may indicate tissue accumulation.  Such accumulation, excessive peak concentrations, advanced age, and cumulative dose may contribute to <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">ototoxicity</span> and <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> (see <span class="Bold"><a href="#ed6f279d-08c7-4236-b4d7-6b6b1e3c810f">PRECAUTIONS</a></span>).  Urine should be examined for decreased specific gravity and increased excretion of protein, cells, and casts.  Blood urea nitrogen, serum creatinine, and creatinine clearance should be measured periodically.  When feasible, it is recommended that serial audiograms be obtained in patients old enough to be tested, particularly high-risk patients.  Evidence of impairment of renal, vestibular, or auditory function requires discontinuation of the drug or dosage adjustment.</p>
<p>Tobramycin should be used with caution in premature and neonatal infants because of their renal immaturity and the resulting prolongation of serum half-life of the drug.</p>
<p>Concurrent and sequential use of other neurotoxic and/or nephrotoxic antibiotics, particularly other aminoglycosides (e.g., amikacin, streptomycin, neomycin, kanamycin, gentamicin, and paromomycin), cephaloridine, viomycin, polymyxin B, colistin, cisplatin, and vancomycin, should be avoided.  Other factors that may increase patient risk are advanced age and <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>.</p>
<p>Aminoglycosides should not be given concurrently with potent diuretics, such as ethacrynic acid and furosemide.  Some diuretics themselves cause <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">ototoxicity</span>, and intravenously administered diuretics enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue.</p>
<p>Aminoglycosides can cause fetal harm when administered to a pregnant woman (see <span class="Bold"><a href="#ed6f279d-08c7-4236-b4d7-6b6b1e3c810f">PRECAUTIONS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="e8f43f05-a856-4948-a6c4-cc9d7eb7f70a"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION:</h1>
<p class="First">Tobramycin sulfate, a water-soluble antibiotic of the aminoglycoside group, is derived from the actinomycete <span class="Italics"><span class="Italics">Streptomyces</span></span> <span class="Italics"><span class="Italics">tenebrarius</span></span>.  Tobramycin Injection, USP is a clear and colorless sterile aqueous solution for parenteral administration.</p>
<p>Each mL contains tobramycin sulfate equivalent to 40 mg tobramycin; sodium metabisulfite 3.2 mg; 0.1 mg edetate disodium and water for injection, qs.  Sulfuric acid and/or sodium hydroxide may have been added to adjust the ph (3.0 to 6.5).</p>
<p>Tobramycin sulfate is <span class="Italics"><span class="Italics">O-</span></span>3-amino-3-deoxy-<span class="Bold"><span class="Italics">α</span></span>-D-glucopyranosyl-(1→4)-<span class="Italics"><span class="Italics">O-</span></span>[2,6-diamino-2,3,6-trideoxy-<span class="Bold"><span class="Italics">α</span></span>-D-<span class="Italics"><span class="Italics">ribo</span></span>-hexopyranosyl-(1→6)]-2-deoxy-L-streptamine, sulfate (2:5)(salt).  The structural formula for tobramycin is as follows:</p>
<p> <img alt="Tobramycin formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8cfeb84f-193a-458a-bdec-205d9274e1a4&amp;name=tobramycin-injection-usp-figure-1-Tobramycin-formula.jpg"></p>
<p><span class="Bold">(C<span class="Sub">18</span>H<span class="Sub">37</span>N<span class="Sub">5</span>O<span class="Sub">9</span>)<span class="Sub">2</span>•5H<span class="Sub">2</span>SO<span class="Sub">4</span>                    M.W. 1425.39</span><br> </p>
<p>The Pharmacy Bulk Package of Tobramycin Injection is a container of a sterile preparation for parenteral use that contains multiple single doses.  It is intended for use in a pharmacy admixture program.  Package use is restricted to the preparation of admixtures for intravenous infusion or to the filling of empty sterile syringes for intravenous injections for patients with individualized dosing requirements.  <span class="Bold">FURTHER DILUTION IS REQUIRED BEFORE USE.</span></p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="f8705e00-64bd-4629-8f39-ca6ecdde4cf6"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY:</h1>
<p class="First">Tobramycin is rapidly absorbed following intramuscular administration.  Peak serum concentrations of tobramycin occur between 30 and 90 minutes after intramuscular administration.  </p>
<p>Following an intramuscular dose of 1 mg/kg of body weight,maximum serum concentrations reach about 4 mcg/mL, and measurable levels persist for as long as 8 hours.  Therapeutic serum levels are generally considered to range from 4 to 6 mcg/mL.  When tobramycin is administered by intravenous infusion over a 1-hour period, the serum concentrations are similar to those obtained by intramuscular administration.  Tobramycin is poorly absorbed from the gastrointestinal tract.</p>
<p>In patients with normal renal function, except neonates, tobramycin administered every 8 hours does not accumulate in the serum.  However, in those patients with reduced renal function and in neonates, the serum concentration of the antibiotic is usually higher and can be measured for longer periods of time than in normal adults.  Dosage for such patients must, therefore, be adjusted accordingly (see <span class="Bold"><a href="#c721df9c-d102-4252-ab73-d86714805616">DOSAGE AND ADMINISTRATION</a></span>).</p>
<p>Following parenteral administration, little, if any, metabolic transformation occurs, and tobramycin is eliminated almost exclusively by glomerular filtration.  Renal clearance is similar to that of endogenous creatinine.  Ultrafiltration studies demonstrate that practically no serum protein binding occurs.  In patients with normal renal function, up to 84% of the dose is recoverable from the urine in 8 hours and up to 93% in 24 hours.</p>
<p>Peak urine concentrations ranging from 75 to 100 mcg/mL have been observed following the intramuscular injection of a single dose of 1 mg/kg.  After several days of treatment, the amount of tobramycin excreted in the urine approaches the daily dose administered.  When renal function is impaired, excretion of tobramycin is slowed, and accumulation of the drug may cause toxic blood levels.</p>
<p>The serum half-life in normal individuals is 2 hours.  An inverse relationship exists between serum half-life and creatinine clearance, and the dosage schedule should be adjusted according to the degree of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (see <span class="Bold"><a href="#c721df9c-d102-4252-ab73-d86714805616">DOSAGE AND ADMINISTRATION</a></span>).  In patients undergoing dialysis, 25% to 70% of the administered dose may be removed, depending on the duration and type of dialysis.</p>
<p>Tobramycin can be detected in tissues and body fluids after parenteral administration.  Concentrations in bile and stools ordinarily have been low, which suggests minimum biliary excretion.  Tobramycin has appeared in low concentration in the cerebrospinal fluid following parenteral administration, and concentrations are dependent on dose, rate of penetration, and degree of meningeal <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>.  It has also been found in <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">sputum</span>, peritoneal fluid, synovial fluid, and <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span> fluids, and it crosses the placental membranes.  Concentrations in the renal cortex are several times higher than the usual serum levels.</p>
<p>Probenecid does not affect the renal tubular transport of tobramycin.</p>
<div class="Section" data-sectionCode="34090-1">
<a name="aac8406d-e268-4f47-9336-dce0f2336745"></a><a name="section-3.1"></a><p></p>
<h2>Microbiology</h2>
<p class="First">Tobramycin is an aminoglycoside antibiotic with activity against Gram-positive and Gram-negative bacteria.</p>
<p><span class="Italics"><span class="Italics">Mechanism of Action</span></span></p>
<p>Tobramycin acts by inhibiting synthesis of protein in bacterial cells.  <span class="Italics"><span class="Italics">In vitro</span></span> tests demonstrate that tobramycin is bactericidal.</p>
<p><span class="Italics"><span class="Italics">Interactions with Other Antibiotics</span></span></p>
<p>Although most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of enterococci demonstrate <span class="Italics"><span class="Italics">in vitro</span></span> resistance, some <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> in this group are susceptible.  <span class="Italics"><span class="Italics">In vitro</span></span> studies have shown that an aminoglycoside combined with an antibiotic that interferes with cell-wall synthesis affects some enterococcal <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> synergistically.  The combination of penicillin G and tobramycin results in a synergistic bactericidal effect <span class="Italics"><span class="Italics">in vitro</span></span> against certain <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics"><span class="Italics">Enterococcus faecalis</span></span>.  However, this combination is not synergistic against other closely related organisms, e.g., <span class="Italics"><span class="Italics">Enterococcus faecium</span></span>.  Speciation of enterococci alone cannot be used to predict susceptibility.  Susceptibility testing and tests for antibiotic synergism are emphasized.</p>
<p><span class="Italics"><span class="Italics">Cross-Resistance</span></span></p>
<p>Cross-resistance between aminoglycosides may occur.</p>
<p>Tobramycin has been shown to be active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following organisms both <span class="Italics"><span class="Italics">in vitro</span></span> and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>: (see <span class="Bold">INDICATIONS AND USAGE</span>). </p>
<p><span class="Bold">Aerobic and facultative Gram-positive microorganisms</span></p>
<p><span class="Italics"><span class="Italics">Staphylococcus aureus</span></span></p>
<p><span class="Bold">Aerobic and facultative Gram-negative microorganisms</span></p>
<p><span class="Italics"><span class="Italics">Citrobacter </span></span>sp</p>
<p><span class="Italics"><span class="Italics">Enterobacter </span></span>sp</p>
<p><span class="Italics"><span class="Italics">Escherichia coli</span></span></p>
<p><span class="Italics"><span class="Italics">Klebsiella </span></span>sp</p>
<p><span class="Italics"><span class="Italics">Morganella morganii  </span></span></p>
<p><span class="Italics"><span class="Italics">Pseudomonas aeruginosa </span></span></p>
<p><span class="Italics"><span class="Italics">Proteus mirabilis</span></span></p>
<p><span class="Italics"><span class="Italics">Proteus vulgaris</span></span></p>
<p><span class="Italics"><span class="Italics">Providencia </span></span>sp</p>
<p><span class="Italics"><span class="Italics">Serratia </span></span>sp</p>
<p>Aminoglycosides have a low order of activity against most gram-positive organisms, including <span class="Italics"><span class="Italics">Streptococcus pyogenes, Streptococcus pneumoniae</span></span>, and enterococci.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="b8eedc66-9323-4921-a6f3-6cbe8de5562a"></a><a name="section-3.2"></a><p></p>
<h2>Susceptibility Tests</h2>
<p class="First">When available, the clinical microbiology laboratory should provide cumulative results of the <span class="Italics"><span class="Italics">in vitro</span></span> susceptibility test results for antimicrobial drugs used in resident hospitals to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens.  These reports should aid the physician in selecting the most effective antimicrobial. </p>
<br><p>Dilution techniques </p>
<br><p>Quantitative methods are used to determine antimicrobial <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MICs).  These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds.  The MICs should be determined using a standardized procedure.  Standardized procedures are based on a dilution method (broth or agar)<span class="Sup">1</span> or equivalent with standardized inoculum concentrations and standardized concentrations of tobramycin powder.  The MIC values should be interpreted according to the criteria provided in Table 1.</p>
<br><p>Diffusion technique</p>
<br><p>Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds.  One such standardized procedure<span class="Sup">2</span> requires the use of standardized inoculum concentrations.  This procedure uses paper disks impregnated with 10 mcg of tobramycin to test the susceptibility of microorganisms to tobramycin.  The disk diffusion interpretive criteria are provided in Table 1.</p>
<br><p><span class="Bold">Table 1:  Susceptibility Interpretive Criteria for Tobramycin</span></p>
<br><table border="0" cellpadding="0" cellspacing="0" width="486"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" rowspan="3" valign="top">
<span class="Italics"><span class="Italics">Pathogen</span></span><br>
</td>
<td class="Rrule" align="center" colspan="6" valign="top"> <br>Susceptibility Interpretive Criteria<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" colspan="3" valign="top"> <br><br>Minimal Inhibitory Concentration (mcg/mL)</td>
<td class="Rrule" align="center" colspan="3" valign="top"> <br><br>Disk Diffusion Zone Diameter (mm)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br><br>S</td>
<td class="Rrule" align="center" valign="top"> <br><br>I</td>
<td class="Rrule" align="center" valign="top"> <br><br>R</td>
<td class="Rrule" align="center" valign="top"> <br><br>S</td>
<td class="Rrule" align="center" valign="top"> <br><br>I</td>
<td class="Rrule" align="center" valign="top"> <br><br>R </td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics"><span class="Italics">Staphylococcus </span></span>spp<span class="Italics"><span class="Italics">.</span></span><br>
</td>
<td class="Rrule" align="center" valign="top"> <br><br>≤4</td>
<td class="Rrule" align="center" valign="top"> <br><br>8</td>
<td class="Rrule" align="center" valign="top">
<br> <br>≥16</td>
<td class="Rrule" align="center" valign="top"> <br><br>≥15</td>
<td class="Rrule" align="center" valign="top">
<br> <br>13 to 14</td>
<td class="Rrule" align="center" valign="top">
<br> <br>≤12</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics"><span class="Italics">Enterobacteriaceae</span></span><br>
</td>
<td class="Rrule" align="center" valign="top"> <br><br>≤4</td>
<td class="Rrule" align="center" valign="top">
<br> <br>8</td>
<td class="Rrule" align="center" valign="top">
<br> <br>≥16</td>
<td class="Rrule" align="center" valign="top"> <br><br>≥15</td>
<td class="Rrule" align="center" valign="top">
<br> <br>13 to 14</td>
<td class="Rrule" align="center" valign="top">
<br> <br>≤12</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">
<span class="Italics"><span class="Italics">Pseudomonas aeruginosa</span></span><br>
</td>
<td class="Rrule" align="center" valign="top"> <br><br>≤4</td>
<td class="Rrule" align="center" valign="top">
<br> <br>8</td>
<td class="Rrule" align="center" valign="top">
<br> <br>≥16</td>
<td class="Rrule" align="center" valign="top"> <br><br>≥15</td>
<td class="Rrule" align="center" valign="top">
<br> <br>13 to 14</td>
<td class="Rrule" align="center" valign="top">
<br> <br>≤12</td>
</tr>
</tbody></table>
<p>A report of Susceptible indicates that the antimicrobial is likely to inhibit growth of the pathogen if the antimicrobial compound in the blood reaches the concentrations usually achievable.  A report of Intermediate indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated.  This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where a high dosage of drug can be used.  This category also provides a buffer zone, which prevents small, uncontrolled technical factors from causing major discrepancies in interpretation. A report of Resistant indicates that the antimicrobial is not likely to inhibit growth of the pathogen if the antimicrobial compound in the blood reaches the concentrations usually achievable and other therapy should be selected.</p>
<br><p><span class="Italics"><span class="Italics">Quality Control</span></span></p>
<br><p>Standardized susceptibility test procedures require the use of quality control microorganisms to control the technical aspects of the test procedures<span class="Sup">3</span>.  Standard tobramycin powder should provide the following range of values noted in Table 2.</p>
<br><p><span class="Bold">Table 2:  Acceptable Quality Control Ranges for Tobramycin</span></p>
<br><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" rowspan="2" valign="top">QC <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">Strain</span><br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top"> <br>Acceptable Quality Control Ranges<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br><br><span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">Minimum Inhibitory Concentration</span> <br>            (mcg/mL)</td>
<td class="Rrule" align="center" valign="top"> <br>Disk Diffusion Zone Diameter (mm)<br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics"><span class="Italics">Staphylococcus aureus</span></span><br>ATCC 29213<br>
</td>
<td class="Rrule" align="center" valign="top"> <br><br>0.12 to 1</td>
<td class="Rrule" align="center" valign="top">
<br> <br>NA<span class="Sup">a</span>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics"><span class="Italics">Staphylococcus aureus</span></span><br>ATCC 25923<br>
</td>
<td class="Rrule" align="center" valign="top"> <br><br>NA</td>
<td class="Rrule" align="center" valign="top">
<br> <br>19 to 29</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics"><span class="Italics">Escherichia coli </span></span><br>ATCC 25922<br>
</td>
<td class="Rrule" align="center" valign="top"> <br><br>0.25 to 1</td>
<td class="Rrule" align="center" valign="top">
<br> <br>18 to 26</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">
<span class="Italics"><span class="Italics">Pseudomonas aeruginosa</span></span><br>ATCC 27853<br>
</td>
<td class="Rrule" align="center" valign="top"> <br><br>0.25 to 1</td>
<td class="Rrule" align="center" valign="top">
<br> <br>19 to 25</td>
</tr>
</tbody></table>
<p><span class="Sup"> a</span> not applicable</p>
<br>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="a1de8efc-0fbd-456d-af4d-10517631882b"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE:</h1>
<p class="First">To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tobramycin Injection, USP and other antibacterial drugs, Tobramycin Injection, USP should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria.  When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.  In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
<p>Tobramycin injection is indicated for the treatment of serious <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span> caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the designated microorganisms in the diseases listed below:</p>
<p><span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">Septicemia</span> in the pediatric patient and adult caused by <span class="Italics"><span class="Italics">P. aeruginosa</span></span>, <span class="Italics"><span class="Italics">E. coli</span></span>, and <span class="Italics"><span class="Italics">Klebsiella</span></span> sp</p>
<p><span class="product-label-link" type="condition" conceptid="4175297" conceptname="Lower respiratory tract infection">Lower respiratory tract infections</span> caused by <span class="Italics"><span class="Italics">P. aeruginos</span></span>a, <span class="Italics"><span class="Italics">Klebsiella </span></span>sp, <span class="Italics"><span class="Italics">Enterobacter</span></span> sp, <span class="Italics"><span class="Italics">Serratia</span></span> sp, <span class="Italics"><span class="Italics">E. coli</span></span>, and <span class="Italics"><span class="Italics">S. aureus</span></span> (penicillinase- and non-penicillinase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)</p>
<p>Serious central-nervous-system <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (<span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>) caused by susceptible organisms</p>
<p>Intra-<span class="product-label-link" type="condition" conceptid="4028062" conceptname="Infectious disease of abdomen">abdominal infections</span>, including <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">peritonitis</span>, caused by <span class="Italics"><span class="Italics">E. coli</span></span>, <span class="Italics"><span class="Italics">Klebsiella </span></span>sp, and <span class="Italics"><span class="Italics">Enterobacter</span></span> sp</p>
<p>Skin, bone, and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by<span class="Italics"><span class="Italics"> P. aeruginosa</span></span>, <span class="Italics"><span class="Italics">Proteus</span></span> sp, <span class="Italics"><span class="Italics">E. coli</span></span>, <span class="Italics"><span class="Italics">Klebsiella</span></span> sp, <span class="Italics"><span class="Italics">Enterobacter </span></span>sp, and <span class="Italics"><span class="Italics">S. aureus</span></span></p>
<p>Complicated and recurrent <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> caused by <span class="Italics"><span class="Italics">P. aeruginosa</span></span>, <span class="Italics"><span class="Italics">Proteus</span></span> sp, (indole-positive and indole-negative), <span class="Italics"><span class="Italics">E. coli</span></span>, <span class="Italics"><span class="Italics">Klebsiella</span></span> sp, <span class="Italics"><span class="Italics">Enterobacter </span></span>sp, <span class="Italics"><span class="Italics">Serratia</span></span> sp, <span class="Italics"><span class="Italics">S. aureus</span></span>,<span class="Italics"><span class="Italics"> Providencia</span></span> sp, and <span class="Italics"><span class="Italics">Citrobacter</span></span> sp.</p>
<p>Aminoglycosides, including tobramycin, are not indicated in uncomplicated initial episodes of <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> unless the causative organisms are not susceptible to antibiotics having less potential toxicity.  Tobramycin may be considered in serious <span class="product-label-link" type="condition" conceptid="435459" conceptname="Staphylococcal infectious disease">staphylococcal infections</span> when penicillin or other potentially less toxic drugs are contraindicated and when bacterial susceptibility testing and clinical judgment indicate its use.</p>
<p>Bacterial cultures should be obtained prior to and during treatment to isolate and identify etiologic organisms and to test their susceptibility to tobramycin.  If susceptibility tests show that the causative organisms are resistant to tobramycin, other appropriate therapy should be instituted.  In patients in whom a serious life-threatening gram-negative <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is suspected, including those in whom concurrent therapy with a penicillin or cephalosporin and an aminoglycoside may be indicated, treatment with tobramycin may be initiated before the results of susceptibility studies are obtained.  The decision to continue therapy with tobramycin should be based on the results of susceptibility studies, the severity of the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, and the important additional concepts discussed in the <span class="Bold"><a href="#b1e05895-f6b8-435b-bae2-014abe7ae553">WARNINGS</a><span class="Italics"> </span></span>box.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="f9154f51-591b-4460-9951-b77224a18ad5"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS:</h1>
<p class="First">A <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any aminoglycoside is a contraindication to the use of tobramycin.  A history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> or serious toxic reactions to aminoglycosides may also contraindicate the use of any other aminoglycoside because of the known cross-sensitivity of patients to drugs in this class.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="f952586f-2a16-4506-98ef-c0120c85bc0e"></a><a name="section-6"></a><p></p>
<h1>WARNINGS:</h1>
<p class="First">See <span class="Bold"><a href="#b1e05895-f6b8-435b-bae2-014abe7ae553">WARNINGS</a></span> box above.</p>
<p>Tobramycin injection contains sodium metabisulfite, a sulfite that may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> episodes, in certain susceptible people.  The overall prevalence of sulfite sensitivity in the general population is unknown and probably low.  Sulfite sensitivity is seen more frequently in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> than in nonasthmatic people. </p>
<p>Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> and dermatologic reactions including <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, and <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span> have been reported rarely in patients on tobramycin therapy.  Although rare, fatalities have been reported (see <span class="Bold"><a href="#f9154f51-591b-4460-9951-b77224a18ad5">CONTRAINDICATIONS</a></span>).</p>
<p>If an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> occurs, the drug should be discontinued and appropriate therapy instituted.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="ed6f279d-08c7-4236-b4d7-6b6b1e3c810f"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS:</h1>
<div class="Section" data-sectionCode="42232-9">
<a name="e79dad51-84ce-4558-a847-0e8e786f72c6"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">Prescribing tobramycin injection in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria. </p>
<p>Serum and urine specimens for examination should be collected during therapy, as recommended in the <span class="Bold"><a href="#b1e05895-f6b8-435b-bae2-014abe7ae553">WARNINGS</a></span> box.  Serum calcium, magnesium, and sodium should be monitored.</p>
<p>Peak and trough serum levels should be measured periodically during therapy.  Prolonged concentrations above 12 mcg/mL should be avoided.  Rising trough levels (above 2 mcg/mL) may indicate tissue accumulation.  Such accumulation, advanced age, and cumulative dosage may contribute to <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">ototoxicity</span> and <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span>.  It is particularly important to monitor serum levels closely in patients with known <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
<p>A useful guideline would be to perform serum level assays after 2 or 3 doses, so that the dosage could be adjusted if necessary, and at 3- to 4-day intervals during therapy.  In the event of changing renal function, more frequent serum levels should be obtained and the dosage or dosage interval adjusted according to the guidelines provided in <span class="Bold"><a href="#c721df9c-d102-4252-ab73-d86714805616">DOSAGE AND ADMINISTRATION</a></span>.</p>
<p>In order to measure the peak level, a serum sample should be drawn about 30 minutes following intravenous infusion or 1 hour after an intramuscular injection.  Trough levels are measured by obtaining serum samples at 8 hours or just prior to the next dose of tobramycin.  These suggested time intervals are intended only as guidelines and may vary according to institutional practices.  It is important, however, that there be consistency within the individual patient program unless computerized pharmacokinetic dosing programs are available in the institution.  These serum-level assays may be especially useful for monitoring the treatment of severely ill patients with changing renal function or of those infected with less susceptible organisms or those receiving maximum dosage.</p>
<p><span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">Neuromuscular blockade</span> and <span class="product-label-link" type="condition" conceptid="4275136" conceptname="Paralysis of diaphragm">respiratory paralysis</span> have been reported in cats receiving very high doses of tobramycin (40 mg/kg).  The possibility of prolonged or secondary <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span> should be considered if tobramycin is administered to anesthetized patients who are also receiving neuromuscular blocking agents, such as succinylcholine, tubocurarine, or decamethonium, or to patients receiving massive transfusions of citrated blood.  If <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">neuromuscular blockade</span> occurs, it may be reversed by the administration of calcium salts. </p>
<p>Cross-allergenicity among aminoglycosides has been demonstrated.</p>
<p>In patients with <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">extensive burns</span> or <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span>, altered pharmacokinetics may result in reduced serum concentrations of aminoglycosides.  In such patients treated with tobramycin, measurement of serum concentration is especially important as a basis for determination of appropriate dosage.</p>
<p>Elderly patients may have reduced renal function that may not be evident in the results of routine screening tests, such as BUN or serum creatinine.  A creatinine clearance determination may be more useful.  Monitoring of renal function during treatment with aminoglycosides is particularly important in such patients.</p>
<p>An increased incidence of <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> has been reported following concomitant administration of aminoglycoside antibiotics and cephalosporins.</p>
<p>Aminoglycosides should be used with caution in patients with muscular disorders, such as <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> or <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span>, since these drugs may aggravate <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> because of their potential curare-like effect on neuromuscular function.</p>
<p>Aminoglycosides may be absorbed in significant quantities from body surfaces after local irrigation or application and may cause <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span> and <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span>.</p>
<p>Aminoglycosides have not been approved for intraocular and/or subconjunctival use.  Physicians are advised that macular <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> has been reported following administration of aminoglycosides, including tobramycin, by these routes.</p>
<p>See <span class="Bold"><a href="#b1e05895-f6b8-435b-bae2-014abe7ae553">WARNINGS</a><span class="Italics"> </span></span>box regarding concurrent use of potent diuretics and concurrent and sequential use of other neurotoxic or nephrotoxic drugs.</p>
<p>The inactivation of tobramycin and other aminoglycosides by ß-lactam-type antibiotics (penicillins or cephalosporins) has been demonstrated<span class="Italics"><span class="Italics"> in vitro</span></span> and in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.  Such inactivation has not been found in patients with normal renal function who have been given the drugs by separate routes of administration.</p>
<p>Therapy with tobramycin may result in overgrowth of nonsusceptible organisms.  If overgrowth of nonsusceptible organisms occurs, appropriate therapy should be initiated.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="fc855f8e-eda7-40a8-b9d0-7641aa1a4f37"></a><a name="section-7.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients should be counseled that antibacterial drugs including tobramycin injection should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>.  They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>).  When tobramycin injection is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed.  Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by tobramycin injection or other antibacterial drugs in the future.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="bd13d8c9-4f61-440a-b221-29234cc616fd"></a><a name="section-7.3"></a><p></p>
<h2>Pregnancy Category D</h2>
<p class="First">Aminoglycosides can cause fetal harm when administered to a pregnant woman.  Aminoglycoside antibiotics cross the placenta, and there have been several reports of total irreversible bilateral <span class="product-label-link" type="condition" conceptid="4318712" conceptname="Congenital deafness">congenital deafness</span> in children whose mothers received streptomycin during pregnancy.  Serious side effects to mother, fetus, or newborn have not been reported in the treatment of pregnant women with other aminoglycosides.  If tobramycin is used during pregnancy or if the patient becomes pregnant while taking tobramycin, she should be apprised of the potential hazard to the fetus.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="e57eb46d-538a-49ab-8637-e28a690f1e9d"></a><a name="section-7.4"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">See <span class="Bold"><a href="#a1de8efc-0fbd-456d-af4d-10517631882b">INDICATIONS AND USAGE</a> </span>and <span class="Bold"><a href="#c721df9c-d102-4252-ab73-d86714805616">DOSAGE AND ADMINISTRATION</a></span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="c6203240-50b8-4721-ba2d-e07d2cde00a6"></a><a name="section-7.5"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Elderly patients may be at a higher risk of developing <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> and <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">ototoxicity</span> while receiving tobramycin (see <span class="Bold"><a href="#f952586f-2a16-4506-98ef-c0120c85bc0e">WARNINGS</a></span>, <span class="Bold"><a href="#ed6f279d-08c7-4236-b4d7-6b6b1e3c810f">PRECAUTIONS</a></span>, and <span class="Bold"><a href="#beccba79-27bf-4286-a658-20e55a14817f">OVERDOSAGE</a></span>).  Other factors that may contribute to <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> and <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">ototoxicity</span> are rising trough levels, excessive peak concentrations, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, concomitant use of other neurotoxic or nephrotoxic drugs, and cumulative dose.  Peak and trough serum levels should be measured periodically during therapy to assure adequate levels and to avoid potentially toxic levels (see <span class="Bold"><a href="#f952586f-2a16-4506-98ef-c0120c85bc0e">WARNINGS</a></span> and <span class="Bold"><a href="#ed6f279d-08c7-4236-b4d7-6b6b1e3c810f">PRECAUTIONS</a></span>).  Tobramycin is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.  Dose reduction is required for patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> (see <span class="Bold"><a href="#c721df9c-d102-4252-ab73-d86714805616">DOSAGE AND ADMINISTRATION</a></span>).  Elderly patients may have reduced renal function that may not be evident in the results of routine screening tests, such as BUN or serum creatinine.  A creatinine clearance determination may be more useful.  Monitoring of renal function during treatment with aminoglycosides is particularly important in the elderly (see <span class="Bold"><a href="#ed6f279d-08c7-4236-b4d7-6b6b1e3c810f">PRECAUTIONS</a></span>).</p>
<p>Tobraymcin 20 mg/2 mL vial contains 1.56 mg (0.068 mEq) of sodium.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="d6ddaf5b-4441-4473-bd40-6d18c48b97d2"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS:</h1>
<div class="Section" data-sectionCode="34084-4">
<a name="a62996b2-b597-468f-a9ab-2a242c111141"></a><a name="section-8.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">Neurotoxicity</span></h2>
<p class="First">Adverse effects on both the vestibular and auditory branches of the eighth nerve have been noted, especially in patients receiving high doses or prolonged therapy, in those given previous courses of therapy with an ototoxin, and in cases of <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>.  Symptoms include <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, roaring in the ears, and <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span>.  <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">Hearing loss</span> is usually irreversible and is manifested initially by diminution of high-tone acuity.  Tobramycin and gentamicin sulfates closely parallel each other in regard to ototoxic potential.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="d59a2d3c-9a7e-4a80-a025-416e98be88fb"></a><a name="section-8.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span></h2>
<p class="First">Renal function changes, as shown by rising BUN, NPN, and serum creatinine and by <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, <span class="product-label-link" type="condition" conceptid="442282" conceptname="Urinary casts">cylindruria</span>, and increased <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>, have been reported, especially in patients with a history of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> who are treated for longer periods or with higher doses than those recommended.  Adverse renal effects can occur in patients with initially normal renal function.</p>
<p>Clinical studies and studies in experimental animals have been conducted to compare the nephrotoxic potential of tobramycin and gentamicin.  In some of the clinical studies and in the animal studies, tobramycin caused <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> significantly less frequently than gentamicin.  In some other clinical studies, no significant difference in the incidence of <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> between tobramycin and gentamicin was found. </p>
<p>Other reported adverse reactions possibly related to tobramycin include <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>, and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>; and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> at the injection site, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">mental confusion</span>, and <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>.  Laboratory abnormalities possibly related to tobramycin include increased serum transaminases (AST, ALT); increased serum LDH and bilirubin; decreased serum calcium, magnesium, sodium, and potassium; and <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span>, and <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="beccba79-27bf-4286-a658-20e55a14817f"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE:</h1>
<div class="Section" data-sectionCode="34088-5">
<a name="c83b9cef-a595-4b06-b760-9a866fe38f96"></a><a name="section-9.1"></a><p></p>
<h2>Signs and Symptoms</h2>
<p class="First">The severity of the signs and symptoms following a tobramycin <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> are dependent on the dose administered, the patient’s renal function, state of hydration, and age and whether or not other medications with similar toxicities are being administered concurrently.  Toxicity may occur in patients treated more than 10 days, in adults given more than 5 mg/kg/day, in pediatric patients given more than 7.5 mg/kg/day, or in patients with reduced renal function where dose has not been appropriately adjusted.</p>
<p><span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span> following the parenteral administration of an aminoglycoside is most closely related to the area under the curve of the serum concentration versus time graph.  <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span> is more likely if trough blood concentrations fail to <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> below 2 mcg/mL and is also proportional to the average blood concentration.  Patients who are elderly, have abnormal renal function, are receiving other nephrotoxic drugs, or are volume depleted are at greater risk for developing <span class="product-label-link" type="condition" conceptid="444044" conceptname="Acute tubular necrosis">acute tubular necrosis</span>.  Auditory and vestibular toxicities have been associated with aminoglycoside <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.  These toxicities occur in patients treated longer than 10 days, in patients with abnormal renal function, in dehydrated patients, or in patients receiving medications with additive auditory toxicities.  These patients may not have signs or symptoms or may experience <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, and a loss of high-tone acuity as <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">ototoxicity</span> progresses.  <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">Ototoxicity</span> signs and symptoms may not begin to occur until long after the drug has been discontinued.</p>
<p><span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">Neuromuscular blockade</span> or <span class="product-label-link" type="condition" conceptid="4275136" conceptname="Paralysis of diaphragm">respiratory paralysis</span> may occur following administration of aminoglycosides.  <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">Neuromuscular blockade</span>, <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span>, and prolonged <span class="product-label-link" type="condition" conceptid="4275136" conceptname="Paralysis of diaphragm">respiratory paralysis</span> may occur more commonly in patients with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> or Parkinson’s disease.  Prolonged <span class="product-label-link" type="condition" conceptid="4275136" conceptname="Paralysis of diaphragm">respiratory paralysis</span> may also occur in patients receiving decamethonium, tubocurarine, or succinylcholine.  If <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">neuromuscular blockade</span> occurs, it may be reversed by the administration of calcium salts but mechanical assistance may be necessary.</p>
<p>If tobramycin were ingested, toxicity would be less likely because aminoglycosides are poorly absorbed from an intact gastrointestinal tract.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="a612c101-3c1b-4bb8-b34d-dd600e0de8b6"></a><a name="section-9.2"></a><p></p>
<h2>Treatment</h2>
<p class="First">In all cases of suspected overdosage, call your Regional Poison Control Center to obtain the most up-to-date information about the treatment of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.  This recommendation is made because, in general, information regarding the treatment of overdosage may change more rapidly than the package insert.  In managing overdosage, consider the possibility of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">multiple drug overdoses</span>, interaction among drugs, and unusual drug kinetics in your patient.</p>
<p>The initial intervention in a tobramycin <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> is to establish an airway and ensure oxygenation and ventilation.  Resuscitative measures should be initiated promptly if <span class="product-label-link" type="condition" conceptid="4275136" conceptname="Paralysis of diaphragm">respiratory paralysis</span> occurs.</p>
<p>Patients who have received an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of tobramycin and who have normal renal function should be adequately hydrated to maintain a urine output of 3 to 5 mL/kg/hr.  Fluid balance, creatinine clearance, and tobramycin plasma levels should be carefully monitored until the serum tobramycin level <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> below 2 mcg/mL.</p>
<p>Patients in whom the elimination half-life is greater than 2 hours or whose renal function is abnormal may require more aggressive therapy.  In such patients, hemodialysis may be beneficial.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="c721df9c-d102-4252-ab73-d86714805616"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION:</h1>
<p class="First"><span class="Bold">This package insert labeling is for a Pharmacy Bulk Package and is intended for preparing intravenous admixtures only.  Dosage recommendations and/or references for the intramuscular route of administration are for informational purposes only</span>. </p>
<p>Tobramycin Injection, USP may be given intramuscularly or intravenously.  Recommended dosages are the same for both routes.  The patient’s pretreatment body weight should be obtained for calculation of correct dosage.  It is desirable to measure both peak and trough serum concentrations (see <span class="Bold"><a href="#b1e05895-f6b8-435b-bae2-014abe7ae553">WARNINGS</a> </span>box and <span class="Bold"><a href="#ed6f279d-08c7-4236-b4d7-6b6b1e3c810f">PRECAUTIONS</a></span>).</p>
<div class="Section" data-sectionCode="34068-7">
<a name="b38c071b-ec1c-4d9a-a0e5-95bec9e79b5c"></a><a name="section-10.1"></a><p></p>
<h2>Administration for Patients with Normal Renal Function</h2>
<p class="First"><span class="Italics"><span class="Italics">Adults with Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>:</span></span>  3 mg/kg/day in 3 equal doses every 8 hours (see Table 3).</p>
<br><p><span class="Italics"><span class="Italics">Adults With Life-Threatening <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>:</span></span>  Up to 5 mg/kg/day may be administered in 3 or 4 equal doses (see Table 3).  The dosage should be reduced to 3 mg/kg/day as soon as clinically indicated. To prevent increased toxicity due to excessive blood levels, dosage should not exceed 5 mg/kg/day unless serum levels are monitored (see <span class="Bold"><a href="#f952586f-2a16-4506-98ef-c0120c85bc0e">WARNINGS</a></span> box and <span class="Bold"><a href="#ed6f279d-08c7-4236-b4d7-6b6b1e3c810f">PRECAUTIONS</a></span>).</p>
<br><p><span class="Bold">Table 3</span><span class="Bold"> <br></span></p>
<br><p><span class="Bold">DOSAGE SCHEDULE GUIDE FOR ADULTS WITH </span></p>
<br><p><span class="Bold">NORMAL RENAL FUNCTION</span></p>
<br><p><span class="Bold">(Dosage at 8-Hour Intervals)</span> </p>
<br><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" colspan="2" valign="top"> <br><span class="Bold">For</span><br> <br><span class="Bold">Patient</span><br><br><span class="Bold">Weighing</span>             <br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top"> <br><span class="Bold">Usual Dose for </span><br> <br><span class="Bold">Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span><br><br><span class="Bold">1 mg/kg q8h</span><br><br><span class="Bold">(Total, 3 mg/kg/day)</span><br><br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">  <span class="Bold">kg</span><br>
</td>
<td class="Rrule" align="center" valign="top">  <span class="Bold">lb</span><br>
</td>
<td class="Rrule" align="center" valign="top">  mg/dose<br>
</td>
<td class="Rrule" align="center" valign="top">  mL/dose*<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" colspan="2" valign="top"><br></td>
<td class="Rrule" align="center" colspan="2" valign="top"> <br>q8h<br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br>120<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>264<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>120 mg<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>3 mL<br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br>115<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>253<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>115 mg<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>2.9 mL<br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br>110<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>242<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>110 mg<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>2.75 mL<br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br>105<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>231<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>105 mg<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>2.6 mL<br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br>100<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>220<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>100 mg<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>2.5 mL<br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br>95<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>209<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>95 mg<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>2.4 mL<br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br>90<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>198<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>90 mg<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>2.25 mL<br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br>85<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>187<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>85 mg<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>2.1 mL<br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br>80<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>176<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>80 mg<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>2 mL<br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br>75<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>165<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>75 mg<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>1.9 mL<br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br>70<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>154<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>70 mg<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>1.75 mL<br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br>65<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>143<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>65 mg<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>1.6 mL<br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br>60<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>132<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>60 mg<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>1.5 mL<br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br>55<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>121<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>55 mg<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>1.4 mL<br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br>50<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>110<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>50 mg<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>1.25 mL<br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br>45<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>99<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>45 mg<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>1.1 mL<br> <br><br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center" valign="top"> <br>40<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>88<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>40 mg<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>1 mL<br> <br><br>
</td>
</tr>
</tbody></table>
<br><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" colspan="2" valign="top"> <br><span class="Bold">For</span><br> <br><span class="Bold">Patient</span><br><br><span class="Bold">Weighing</span><br><br><br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top"> <br><span class="Bold">Maximum Dose for Life-</span><br> <br><span class="Bold">Threatening <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span><br><br><span class="Bold"><span class="Underline">(Reduce as soon as possible)</span></span><br><br><span class="Bold">1.66 mg/kg q8h</span><br><br><span class="Bold">(Total, 5 mg/kg/day)</span><span class="Bold"> <br></span><br><br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <span class="Bold">kg</span><br>
</td>
<td class="Rrule" align="center" valign="top"> <span class="Bold"> lb</span><br>
</td>
<td class="Rrule" align="center" valign="top">mg/dose <br>
</td>
<td class="Rrule" align="center" valign="top">mL/dose* <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" colspan="2" valign="top"><br></td>
<td class="Rrule" align="center" colspan="2" valign="top"> <br>q8h<br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br>120<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>264<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>200 mg<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>5 mL<br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br>115<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>253<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>191 mg<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>4.75 mL<br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br>110<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>242<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>183 mg<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>4.5 mL<br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br>105<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>231<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>175 mg<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>4.4 mL<br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br>100<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>220<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>166 mg<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>4.2 mL<br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br>95<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>209<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>158 mg<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>4 mL<br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br>90<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>198<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>150 mg<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>3.75 mL<br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br>85<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>187<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>141 mg<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>3.5 mL<br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br>80<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>176<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>133 mg<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>3.3 mL<br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br>75<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>165<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>125 mg<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>3.1 mL<br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br>70<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>154<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>116 mg<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>2.9 mL<br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br>65<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>143<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>108 mg<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>2.7 mL<br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br>60<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>132<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>100 mg<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>2.5 mL<br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br>55<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>121<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>91 mg<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>2.25 mL<br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br>50<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>110<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>83 mg<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>2.1 mL<br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br>45<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>99<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>75 mg<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>1.9 mL<br> <br><br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center" valign="top"> <br>40<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>88<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>66 mg<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>1.6 mL<br> <br><br>
</td>
</tr>
</tbody></table>
<p>*Applicable to all product forms except the tobramycin injection for pediatric use, 10 mg/mL (see <span class="Bold"><a href="#c54c8d3c-9c14-4417-bb4a-209621617bcd">HOW SUPPLIED</a></span>).</p>
<br><br><br><p><span class="Italics"><span class="Italics">Pediatric Patients (greater than 1 week of age):</span></span>  6 to 7.5 mg/kg/day in 3 or 4 equally divided doses (2 to 2.5 mg/kg every 8 hours or 1.5 to 1.89 mg/kg every 6 hours). </p>
<br><p><span class="Italics"><span class="Italics">Premature or Full-Term Neonates 1 Week of Age or Less:</span></span>  Up to 4 mg/kg/day may be administered in 2 equal doses every 12 hours.</p>
<br><p>It is desirable to limit treatment to a short term.  The usual duration of treatment is 7 to 10 days.  A longer course of therapy may be necessary in difficult and complicated <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.  In such cases, monitoring of renal, auditory, and vestibular functions is advised, because <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span> is more likely to occur when treatment is extended longer than 10 days.</p>
<br>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ace293b4-9bd0-4e83-8995-18c0668e6279"></a><a name="section-10.2"></a><p></p>
<h2>Dosage in Patients with <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">Cystic Fibrosis</span></h2>
<p class="First">In patients with <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span>, altered pharmacokinetics may result in reduced serum concentrations of aminoglycosides.  Measurement of tobramycin serum concentration during treatment is especially important as a basis for determining appropriate dose.  In patients with severe <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span>, an initial dosing regimen of 10 mg/kg/day in 4 equally divided doses is recommended.  This dosing regimen is suggested only as a guide.  The serum levels of tobramycin should be measured directly during treatment due to wide interpatient variability. </p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="e53d5691-1119-4073-b083-cb87b79c380c"></a><a name="section-10.3"></a><p></p>
<h2>Administration for Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></h2>
<p class="First">Whenever possible, serum tobramycin concentrations should be monitored during therapy.</p>
<p>Following a loading dose of 1 mg/kg, subsequent dosage in these patients must be adjusted, either with reduced doses administered at 8-hour intervals or with normal doses given at prolonged intervals.  Both of these methods are suggested as guides to be used when serum levels of tobramycin cannot be measured directly.  They are based on either the creatinine clearance level or the serum creatinine level of the patient because these values correlate with the half-life of tobramycin.  The dosage schedule derived from either method should be used in conjunction with careful clinical and laboratory observations of the patient and should be modified as necessary.  Neither method should be used when dialysis is being performed.</p>
<p><span class="Underline">Reduced dosage at 8-hour intervals</span>:  When the creatinine clearance rate is 70 mL or less per minute or when the serum creatinine value is known, the amount of the reduced dose can be determined by multiplying the normal dose from Table 3 by the percent of normal dose from the accompanying nomogram.</p>
<p>An alternate rough guide for determining reduced dosage at 8-hour intervals (for patients whose steady-state serum creatinine values are known) is to divide the normally recommended dose by the patient’s serum creatinine.</p>
<p><img alt="scale" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8cfeb84f-193a-458a-bdec-205d9274e1a4&amp;name=tobramycin-injection-usp-figure-2-tobra-scale.jpg"> </p>
<p>* Scales have been adjusted to facilitate dosage calculations. </p>
<p><span class="Underline">Normal dosage at prolonged intervals</span>:  If the creatinine clearance rate is not available and the patient’s condition is stable, a dosage frequency <span class="Italics"><span class="Italics">in hours</span></span> for the dosage given in Table 3 can be determined by multiplying the patient’s serum creatinine by 6.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="d921d91a-5af0-4662-9161-a73f909a08a7"></a><a name="section-10.4"></a><p></p>
<h2>Dosage in Obese Patients</h2>
<p class="First">The appropriate dose may be calculated by using the patient’s estimated lean body weight plus 40% of the excess as the basic weight on which to figure mg/kg.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="dbdcbf2b-3ee8-42ef-bd3a-1eb969847342"></a><a name="section-10.5"></a><p></p>
<h2>Intravenous Administration</h2>
<p class="First">For intravenous administration, the usual volume of diluent (0.9% Sodium Chloride Injection or 5% Dextrose Injection) is 50 to 100 mL for adult doses.  For pediatric patients, the volume of diluent should be proportionately less than that for adults.  The diluted solution usually should be infused over a period of 20 to 60 minutes.  Infusion periods of less than 20 minutes are not recommended because peak serum levels may exceed 12 mcg/mL (see <span class="Bold"><a href="#b1e05895-f6b8-435b-bae2-014abe7ae553">WARNINGS</a></span> box).</p>
<p>Tobramycin injection, USP should not be physically premixed with other drugs but should be administered separately according to the recommended dose and route.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="a897aa5b-a724-4892-b113-3bff5e839f4c"></a><a name="section-11"></a><p></p>
<h1>PREPARATION AND STORAGE:</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="f6f8c32d-e30e-4f90-980c-6fa12c06ef92"></a><a name="section-11.1"></a><p></p>
<h2>Directions for Proper Use of Pharmacy Bulk Package Use Aseptic Technique-Not for Direct Infusion</h2>
<p class="First">The Pharmacy Bulk Package is for use in a Pharmacy Admixture Service only in a suitable work area, such as a laminar flow hood.  </p>
<ol class="Arabic">
<li>For hanger use, grasp portion of the bottle label marked "LIFT HERE".  Peel the laminated film (sling) away from the printed portion of the pressure sensitive label.  Invert bottle and pull sling over the base of the bottle.  Hang bottle using sling portion of the label.</li>
<li>Remove cover from closure and cleanse with antiseptic.</li>
<li>Using aseptic technique enter the vial only 1 time using a suitable sterile transfer device or dispensing set which allows measured dispensing of the contents.  Use of a syringe and needle is not recommended as it may cause leakage.  Transfer individual doses to appropriate intravenous infusion solutions without delay.  AFTER INITIAL ENTRY USE ENTIRE CONTENTS OF VIAL PROMPTLY.  ANY UNUSED PORTION MUST BE DISCARDED WITHIN <span class="Bold">4 HOURS</span>.</li>
</ol>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="c54c8d3c-9c14-4417-bb4a-209621617bcd"></a><a name="section-12"></a><p></p>
<h1>HOW SUPPLIED:</h1>
<p class="First">Tobramycin Injection USP, in the Pharmacy Bulk Package, is supplied as follows: </p>
<br><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Product   </span><br><span class="Bold">No.</span><br>
</td>
<td class="Rrule" valign="top">
<span class="Bold">NDC</span><br><span class="Bold">No.</span><br>
</td>
<td class="Rrule" align="left" valign="top"> <br><span class="Bold">Strength</span><br> <br><br>
</td>
<td class="Rrule" align="left" valign="top"> <br><span class="Bold">Fill Volume<br></span><br> <br><br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">300751<br>
</td>
<td class="Rrule" valign="top">63323-307-51     <br>
</td>
<td class="Rrule" valign="top">2 g per 50 mL<br>(40 mg per mL)         <br>
</td>
<td class="Rrule" valign="top">50 mL in a 60 mL vial, packaged individually.<br>
</td>
</tr>
</tbody></table>
<p>Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].</p>
<br><p>This container closure is not made with natural rubber latex.</p>
<br><p>Tobramycin Injection, USP, is also available in multiple dose vials: </p>
<br><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Product </span><br><span class="Bold">No.</span><br>
</td>
<td class="Rrule" valign="top">
<span class="Bold">NDC</span><br><span class="Bold">No.</span><br>
</td>
<td class="Rrule" align="left" valign="top"> <br><span class="Bold">Strength</span><br> <br><br>
</td>
<td class="Rrule" align="left" valign="top">
<span class="Bold">Fill Volume</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">300502<br>
</td>
<td class="Rrule" valign="top">63323-305-02<br>
</td>
<td class="Rrule" valign="top">20 mg per 2 mL<br>(10 mg per mL)      <br>
</td>
<td class="Rrule" valign="top">2 mL in a 2 mL vial, packaged in 25.<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">300602<br>
</td>
<td class="Rrule" valign="top">63323-306-02<br>
</td>
<td class="Rrule" valign="top">80 mg per 2 mL<br>(40 mg per mL)<br>
</td>
<td class="Rrule" valign="top">2 mL in a 2 mL  vial, packaged in 25.<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">300630<br>
</td>
<td class="Rrule" valign="top">63323-306-30<br>
</td>
<td class="Rrule" valign="top">1.2 g per 30 mL<br>(40 mg per mL)<br>
</td>
<td class="Rrule" valign="top">30 mL in a 30 mL vial, packaged in 10.<br>
</td>
</tr>
</tbody></table>
<br>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="bde6c1e0-4c2b-4dd1-8598-e05edf603221"></a><a name="section-13"></a><p></p>
<h1>REFERENCES</h1>
<ol class="Arabic">
<li>
<span class="Italics"><span class="Italics">Methods for Dilution Antimicrobial Susceptibility Tests</span></span> <span class="Italics"><span class="Italics">for Bacteria That Grow Aerobically;</span></span> Approved Standard—8th ed., CLSI document M07-A8. Clinical and Laboratory Standards Institute, Wayne, PA. January, 2009. </li>
<li>
<span class="Italics"><span class="Italics">Performance Standards for Antimicrobial Susceptibility Testing</span></span>; 21st Informational Supplement. CLSI document M100-S21.  Clinical and Laboratory Standards Institute, Wayne, PA. January, 2011. </li>
<li>
<span class="Italics"><span class="Italics">Performance Standards for Antimicrobial Disk Susceptibility Tests</span></span>; Approved Standard—10 th ed., CLSI document M02-A10.  Clinical and Laboratory Standards Institute, Wayne, PA. January, 2009. </li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="da196bf4-3ae0-44a8-b938-6134a1f1bcf3"></a><a name="section-14"></a><p></p>
<p class="First"><img alt="logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8cfeb84f-193a-458a-bdec-205d9274e1a4&amp;name=tobramycin-injection-usp-figure-3-fk-address.jpg"> </p>
<p>45964F</p>
<p>Revised: June 2014</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="fdf854fd-143a-4835-9546-bbf7582a87e4"></a><a name="section-15"></a><p></p>
<p class="First"><span class="Bold">PACKAGE LABEL - PRINCIPAL DISPLAY - Tobramycin 50 mL Vial Label</span></p>
<p><span class="Bold">NDC</span> 63323-307-51</p>
<p>300751<br><span class="Bold">Tobramycin Injection, USP<br>2 g per 50 mL</span> <br><span class="Bold">40 mg per mL <br></span></p>
<p>Pharmacy Bulk Package - Not for Direct Infusion</p>
<p>For Intravenous Use*</p>
<p>Rx only</p>
<p>*Must be diluted before IV use.</p>
<p>This package is not intended to be dispensed as a unit.</p>
<p><img alt="402103D-vial" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8cfeb84f-193a-458a-bdec-205d9274e1a4&amp;name=300751-vial.jpg"> </p>
<br><br><p><span class="Bold">PACKAGE LABEL - PRINCIPAL DISPLAY - Tobramycin 50 mL Vial Carton Panel </span></p>
<p><span class="Bold">NDC</span> 63323-307-51</p>
<p>300751<br><span class="Bold">Tobramycin Injection, USP</span></p>
<p><span class="Bold">2 g per 50 mL</span></p>
<p><span class="Bold">40 mg per mL<br></span></p>
<p>Pharmacy Bulk Package - Not for Direct Infusion</p>
<p>For Intravenous Use*</p>
<p>*Must be diluted before IV use.</p>
<p>This package is not intended to be dispensed as a unit.</p>
<p>Rx only</p>
<br><p><img alt="62786F-pbox" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8cfeb84f-193a-458a-bdec-205d9274e1a4&amp;name=300751-pbox.jpg"> </p>
<br>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TOBRAMYCIN 		
					</strong><br><span class="contentTableReg">tobramycin sulfate injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63323-307</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TOBRAMYCIN SULFATE</strong> (TOBRAMYCIN) </td>
<td class="formItem">TOBRAMYCIN</td>
<td class="formItem">40 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM METABISULFITE</strong></td>
<td class="formItem">3.2 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>EDETATE DISODIUM</strong></td>
<td class="formItem">0.1 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SULFURIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63323-307-51</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">50 mL in 1 VIAL, PHARMACY BULK PACKAGE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA065120</td>
<td class="formItem">11/30/2004</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Fresenius Kabi USA, LLC
							(608775388)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Fresenius Kabi USA, LLC</td>
<td class="formItem"></td>
<td class="formItem">840771732</td>
<td class="formItem">MANUFACTURE(63323-307)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 7/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>a25f477a-3f7a-4dca-9520-f7d596b6447e</div>
<div>Set id: 8cfeb84f-193a-458a-bdec-205d9274e1a4</div>
<div>Version: 2</div>
<div>Effective Time: 20140703</div>
</div>
</div> <div class="DistributorName">Fresenius Kabi USA, LLC</div></p>
</body></html>
